Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bladder cancer.

Lester S Borden1, Peter E Clark, M Craig Hall

  • 1Department of Urology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA. mchall@wfubmc.edu

Current Opinion in Oncology
|April 8, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Re: Durvalumab in combination with BCG for BCG-naive, high risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.

European urology·2026
Same author

Racial and socioeconomic disparities from time of diagnosis to treatment for small renal masses.

BJUI compass·2026
Same author

Protocol-driven same day discharge for robotic radical prostatectomy.

Urologic oncology·2025
Same author

Diagnostic yield of upper tract imaging performed for hematuria screening: Results from a national, privately-insured cohort.

Urologic oncology·2024
Same author

Change in prostate tissue gene expression following finasteride or doxazosin administration in the medical therapy for prostatic symptoms (MTOPS) study.

Scientific reports·2024
Same author

Reply by Authors.

Urology practice·2024
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Recent bladder cancer research highlights bacillus Calmette-Guerin (BCG) as effective intravesical therapy for superficial tumors. For muscle-invasive disease, chemotherapy and surgical approaches are improving patient survival rates.

Area of Science:

  • Urology
  • Oncology
  • Cancer Research

Background:

  • Bladder cancer presents a significant global health challenge, contributing to substantial morbidity and mortality.
  • Ongoing research aims to enhance diagnostic accuracy and therapeutic strategies for bladder cancer patients.

Purpose of the Study:

  • To review recent advancements in the diagnosis and management of bladder cancer.
  • To synthesize current evidence on effective treatments for various stages of bladder cancer.

Main Methods:

  • Literature review of recent studies on bladder cancer diagnosis and treatment.
  • Analysis of evidence regarding intravesical therapies, surgical interventions, and chemotherapy.

Main Results:

  • Bacillus Calmette-Guerin (BCG) is identified as the most effective intravesical therapy for superficial bladder cancer, with maintenance therapy outperforming induction alone.

Related Experiment Videos

  • Nodal status and extent of lymphadenectomy are critical prognostic factors for survival following radical cystectomy in muscle-invasive bladder cancer.
  • Neoadjuvant chemotherapy has demonstrated a survival benefit, and research is actively defining optimal chemotherapy regimens for urothelial carcinoma.

    • Conclusions:

    • Advances in understanding and managing all stages of bladder cancer are leading to improved patient outcomes.
    • Continued research into novel diagnostic and therapeutic approaches is crucial for further enhancing bladder cancer care.